Allstate Corporation’s NovoCure NVCR Stock Holding History

Allstate Corporation’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,956	Closed	-$290K	–	451
2022 Q4	$290K	Buy	3,956 +85	+2%	+$6.4K	0.01%	554
2022 Q3	$294K	Sell	3,871 -18	-0.5%	-$1.4K	0.01%	560
2022 Q2	$270K	Sell	3,889 -791	-17%	-$59.6K	0.01%	578
2022 Q1	$388K	Buy	+4,680	New	+$345K	0.01%	540
2021 Q4	–	Sell	-2,979	Closed	-$346K	–	756
2021 Q3	$346K	Buy	2,979 +519	+21%	+$78.5K	0.01%	593
2021 Q2	$546K	Buy	+2,460	New	+$479K	0.02%	500
2021 Q1	–	Sell	-1,195	Closed	-$207K	–	737
2020 Q4	$207K	Buy	+1,195	New	+$164K	0.01%	692

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Allstate Corporation's NVCR Position: Q1 2023 in Review

Allstate Corporation sold out of NovoCure (NVCR) in Q1 2023, closing a stake of 3,956 shares — an estimated $290K sold.

Allstate Corporation first reported a position in NVCR in Q4 2020 and held it in 7 quarters. The position peaked at $546K in Q2 2021. 295 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

Allstate Corporation reported no remaining NovoCure position as of Q1 2023 after selling out during the quarter.
Allstate Corporation sold 3,956 NovoCure shares in Q1 2023, an estimated $290K.
Allstate Corporation first reported a position in NovoCure in Q4 2020 and held it in 7 quarters.
Allstate Corporation's NovoCure position peaked at $546K in Q2 2021.
295 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on Allstate Corporation's 13F filing for Q1 2023, filed 10 May 2023.